Professional article
Open access

Jusqu'où et jusqu'à quand traiter l'ostéoporose?

Published inRevue médicale suisse, vol. 13, no. 559, p. 859-862
Publication date2017

Estrogen replacement therapy, selective modulators of the estrogen receptor (SERMs), bisphophonates and denosumab are antiresorptive therapies which can be used for several years. Teriparatide is still the only bone forming agent available, its use is limited to 24 months. Except the absence of new fragility fractures, there is no well defined target in the treatment of osteoporosis. Nevertheless persistence of high fracture risk (prevalent fractures and/or low BMD) on therapy indicates to maintain or intensify the treatment. On the contrary, if fracture risk is low, a « therapeutic window » could be considered after treatment with bisphosphonates, whereas after denosumab a short course of another treatment may be necessary.

  • Bone Density
  • Bone Density Conservation Agents/administration & dosage
  • Estrogen Replacement Therapy/methods
  • Humans
  • Osteoporosis/complications/drug therapy
  • Osteoporotic Fractures/prevention & control
  • Selective Estrogen Receptor Modulators/administration & dosage
  • Teriparatide/administration & dosage
  • Time Factors
Citation (ISO format)
UEBELHART, Brigitte Florence, FERRARI, Serge Livio. Jusqu’où et jusqu’à quand traiter l’ostéoporose? In: Revue médicale suisse, 2017, vol. 13, n° 559, p. 859–862.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation07/04/2018 10:51:00 AM
First validation07/04/2018 10:51:00 AM
Update time03/15/2023 8:28:35 AM
Status update03/15/2023 8:28:35 AM
Last indexation01/17/2024 3:17:41 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack